Medical Devices
Technology
Health

Becton Dickinson

$248.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.98 (0.80%) Today
$0.00 (0.00%) As of 4:12 PM EDT after-hours

Why Robinhood?

You can buy or sell BDX and other stocks, options, ETFs, and crypto commission-free!

About BDX

Becton, Dickinson and Co., also called Becton Dickinson, is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Read More The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Employees
76,032
Headquarters
Franklin Lakes, New Jersey
Founded
1897
Market Cap
67.04B
Price-Earnings Ratio
87.13
Dividend Yield
1.15
Average Volume
1.30M
High Today
$248.93
Low Today
$247.07
Open Price
$248.26
Volume
761.34K
52 Week High
$265.87
52 Week Low
$208.62

Collections

Medical Devices
Technology
Health
Medical
Healthcare
Pharmaceutical
Media
Cancer Prevention

BDX News

ReutersAug 6

Edited Transcript of BDX earnings conference call or presentation 6-Aug-19 12:00pm GMT

15
BenzingaAug 6

Mid-Afternoon Market Update: Dow Up Over 300 Points; Dean Foods Shares Drop On Downbeat Q2 Results

29
BenzingaAug 6

Mid-Day Market Update: EverQuote Surges Following Strong Q2 Results; GreenSky Shares Plummet

4

BDX Earnings

$2.41
$2.63
$2.86
$3.08
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
$3.05 per share
Actual
$3.08 per share

More BDX News

BenzingaAug 6

Becton Dickinson Reports Mixed Q3 Earnings, Reaffirms Guidance

7
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.